Allergan Sees Hope In Poor Botox Depression Data
Allergan has decided to pursue Botox in Phase III as a treatment for depression, despite a Phase II trial not meeting its primary endpoint and failing to show a dose response. One analyst has suggested the company is merely attempting to shore up off-label sales.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.